ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL THERAPIES: CHANGING INDICATIONS AND DYNAMIC RISK ASSESSMENT
Allogeneic HSCT remains a major potentially curative treatment for patients with AML at high risk of relapse. However, the rapid development of targeted agents and novel non-intensive therapies has substantially changed the therapeutic landscape, raising questions regarding the optimal timing and indications for transp...